I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
XENERA-1: a randomised double-blind Phase II trial of xentu..:
Peter Schmid
;
Javier Cortes
;
Ana Joaquim
...
https://doi.org/10.1186/s13058-023-01649-w. , 2023
Link:
https://doi.org/10.1186/s13058-023-01649-w
RT Journal T1
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:a82c233f1d464fc4a9406c96e34873dd&Exemplar=1&LAN=DE A1 Peter Schmid A1 Javier Cortes A1 Ana Joaquim A1 Noelia Martínez Jañez A1 Serafín Morales A1 Tamara Díaz-Redondo A1 Sibel Blau A1 Patrick Neven A1 Julie Lemieux A1 José Ángel García-Sáenz A1 Lowell Hart A1 Tsvetan Biyukov A1 Navid Baktash A1 Dan Massey A1 Howard A. Burris A1 Hope S. Rugo PB BMC YR 2023 K1 Advanced breast cancer K1 HR+/HER2− K1 Non-visceral disease K1 Xentuzumab K1 Insulin-like growth factor K1 Everolimus K1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens K1 RC254-282 JF https://doi.org/10.1186/s13058-023-01649-w LK http://dx.doi.org/https://doi.org/10.1186/s13058-023-01649-w DO https://doi.org/10.1186/s13058-023-01649-w SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)